ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > The Big IF

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon Jun 02, 2022 7:38pm

157 Views

Post# 34728106

RE:RE:RE:The Big IF

No i mean before the start of phase 1. If they can't partner this with milestones that equal results then there is not much enthusiam amongst pharma for there products. Important to remember pharma didn't think they could get to phase1 but that's changed. Why would they bother to spend anymore on ALS and PD killing more mice to support past results. Those programs don't have a chance in getting off the ground unless they can produce partnerships.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market